Long alimentary-limb versus long biliary-limb Roux-en-Y gastric bypass for diabetes remission
Official title: Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients. A Prospective, Multicentric, Randomized, Controlled Trial.
Run by University Hospital, Lille · NCT03821636 · Data updated 2026-11-12
This tests whether, for people with severe obesity and type 2 diabetes, two variants of Roux-en-Y gastric bypass with a short common limb—one with a long alimentary limb and one with a long biliary limb—lead to higher rates of diabetes remission.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 396 (estimated) |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 4 sites (Amiens and 3 other locations) |
| Status | Recruiting |
| Started | June 16, 2019 |
| Main results expected | June 2026 |
| Study ends | June 2026 |
| Registry record updated | December 23, 2025 |
| Trial ID | NCT03821636 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with BMI ≥35 kg/m2 who have type 2 diabetes and are eligible for bariatric surgery under French guidelines, and who have not had prior obesity surgery.
✕Probably not a fit
Patients with prior bariatric surgery, severe non-stabilized psychiatric or eating disorders, active substance dependence, unstable life‑threatening disease, or contraindications to general anesthesia are unlikely to benefit from enrollment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Roux-en-Y gastric bypass (RYGB) often improves blood sugar control rapidly and beyond what weight loss alone would predict, possibly because food is redirected away from the proximal intestine and glucose absorption shifts to the common limb. This study compares two RYGB configurations that both use a short common limb but differ in whether the alimentary limb or the biliary limb is lengthened. Eligible patients (BMI ≥35 kg/m2 with type 2 diabetes and suitable for bariatric surgery) will undergo one of the two surgical variants and be followed for metabolic outcomes including diabetes remission and postprandial glucose excursions. The trial aims to clarify whether limb-length configuration influences glycemic outcomes and could inform surgical planning.
Why it matters
Potential benefit: If successful, the results could identify a surgical configuration that improves the chance of diabetes remission and better post-meal glucose control in severely obese patients.
How similar studies have gone: RYGB is well established to improve glycemic control, but high-quality evidence specifically comparing the metabolic effects of differing alimentary versus biliary limb lengths with a short common limb is limited and inconclusive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI ≥ 35 kg/m2 * All patient with type 2 diabetes * Patients who were candidates for obesity surgery in accordance with French recommendation Exclusion Criteria: * Severe cognitive or mental disorders * patient who have already undergone obesity surgery * Severe and non-stabilised eating disorders * The likely inability of the patient to participate in lifelong medical follow-up * Alcohol or psychoactive substances dependence * The absence of identified prior medical management of obesity * Diseases that are life-threatening in the short and medium term; * Contraindications to general anaesthesia.
Where it's running
-
Chu Amiens Picardie
Amiens, France Recruiting -
Ch Boulogne-Sur-Me
Boulogne-sur-Mer, France Recruiting -
Hop Claude Huriez Chu Lille
Lille, France Recruiting -
Ch de Valenciennes
Valenciennes, France Recruiting
Study contacts
- Principal investigator: Grégory BAUD, MD — University Hospital, Lille
- Study coordinator: Grégory BAUD, MD
- Email: gregory.baud@chru-lille.fr
- Phone: 3.20.44.42.73
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-carbohydrate diet for normalizing blood sugar in type 2 diabetes
This study tests if a low-carbohydrate diet can help people with type 2 diabetes lower their blood sugar levels better than traditional calorie counting.
-
Measuring a new biomarker in obese children with or without type 2 diabetes
This study is testing a new blood marker in obese kids aged 12 to 16, with and without type 2 diabetes, to see if it can help understand how their bodies manage sugar.
-
Lifestyle program plus weekly semaglutide for older adults with type 2 diabetes and obesity
In adults aged 65 and older with type 2 diabetes and obesity, this study tests whether adding an online exercise program and personalized nutrition to weekly semaglutide helps slow muscle and physical function decline more than semaglutide with general health advice.
-
Effects of Pioglitazone on Heart Failure in Obese Type 2 Diabetics
This study is testing if the diabetes drug Pioglitazone can help improve heart function in obese people with type 2 diabetes and heart failure.
-
Investigating brain health in youth at risk for type 2 diabetes
This study is trying to see how being overweight or having blood sugar issues affects brain health in kids aged 12-17 who might be at risk for type 2 diabetes.
-
Weight loss pill (BGM0504) in adults who are overweight or obese, without diabetes
This trial tests whether BGM0504 tablets help overweight or obese adults without diabetes lose weight compared with a placebo over 20 weeks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.